Biogen Indec Inc.’s website for Avonex (interferon beta-1a) triggered an untitled letter from FDA, which said the company was overstating the efficacy of the multiple sclerosis drug and implying it is superior to four other products.
FDA’s Office of Prescription Drug Promotion objected to a chart on a web page titled “Multiple Sclerosis Treatments,” comparing Avonex...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?